The hematological response to continuous ambulatory peritoneal dialysis

Area of Science:

• Nephrology
• Hematology

Background:

• Continuous ambulatory peritoneal dialysis (CAPD) is a common treatment for end-stage renal disease.
• Anemia is a frequent complication in patients undergoing dialysis.

Purpose of the Study:

• To investigate the hematological response, specifically hemoglobin (Hb) levels, in new CAPD patients over the initial three months of therapy.
• To determine the factors contributing to changes in Hb, including red cell mass (RCM) and erythropoietin (EPO) levels.

Main Methods:

• A prospective study of 8 previously non-transfused patients initiating CAPD.
• Regular monitoring of hemoglobin, red cell mass (RCM), plasma volume (PV), serum vitamin B12, folate, ferritin, and bio-assayable erythropoietin (EPO) over three months.

Main Results:

• Mean Hb increased by +2.78 g/dl (P < 0.02).
• Mean RCM increased significantly (by 37.7% and 29.6% in absolute and weight-adjusted values, respectively; P < 0.05).
• Plasma volume fell relative to body weight (P < 0.05), while EPO levels were generally normal but inappropriately low for the degree of anemia and did not change significantly.

Conclusions:

• The initial three months of CAPD therapy lead to a significant increase in Hb in most patients.
• This Hb rise is primarily driven by an increase in red cell mass (RCM).
• The observed hematological improvement is largely independent of changes in serum erythropoietin (EPO) levels during this period.